What does an earnings surprise mean?

An earnings surprise is the difference between a company's reported EPS or revenue and the analysts' consensus estimate. A positive surprise means results exceeded expectations, while a negative surprise means results fell short.

How can earnings reports affect ANIP stock?

Earnings reports can increase volatility in ANIP stock, especially when reported EPS, revenue or company guidance differs from market expectations. An earnings beat does not always lead to a price increase, as investors also consider the outlook, valuation and broader market conditions.

ANI Pharmaceuticals Inc Earnings Dates & Reports

This page offers detailed ANI Pharmaceuticals Inc earnings data including the latest ANI Pharmaceuticals Inc earnings report, the upcoming ANI Pharmaceuticals Inc earnings date, historical data and ANI Pharmaceuticals Inc earnings call news.

ANIP Latest Quarter’s Earnings

Announce Date8/7/2026

EPS Actual (USD)1.17

Revenue Actual (USD)266.04M

ANIP Upcoming Quarter's Earnings

Announce Date--

EPS Forecast (USD)--

Revenue Forecast (USD)--

ANIP FY2025 Earnings

EPS (YoY)3.50435.75%

Revenue (YoY)883.37M43.78%

ANI Pharmaceuticals Inc (ANIP) Earnings History

Release Date	Period End	EPS/Forecast	Revenue/Forecast	EPS Surprise %	Revenue Surprise %
8/7/2026	06/2026	1.17/2.05	266.04M/260.13M	-43.03%	2.27%
5/8/2026	03/2026	1.31/1.30	237.46M/207.57M	0.52%	14.40%
2/27/2026	12/2025	1.23/2.00	247.06M/231.53M	-38.51%	6.71%
11/7/2025	09/2025	1.19/1.75	227.81M/211.04M	-32.42%	7.95%
8/8/2025	06/2025	0.37/1.42	211.37M/190.29M	-74.00%	11.08%
5/9/2025	03/2025	0.70/1.38	197.12M/180.68M	-49.42%	9.10%
2/28/2025	12/2024	-0.55/1.44	190.57M/175.37M	-138.28%	8.67%
11/8/2024	09/2024	-1.27/1.09	148.33M/144.35M	-216.61%	2.76%

ANI Pharmaceuticals Inc Earnings News

ANI Q2 2026 earnings: Cortrophin drives 25.9% revenue growth

ANI Pharmaceuticals’ Q2 2026 net revenue rose 25.9% to $266.0 million, while diluted GAAP EPS increased to $1.05 from $0.36 and adjusted EBITDA climbed 32.4% to $71.6 million. Cortrophin Gel remained the main driver, with revenue up 43.5% to $117.1 million, although GAAP gross margin narrowed to 62.4%. ANI reaffirmed its $1.08-$1.14 billion full-year revenue outlook and $285-$300 million adjusted EBITDA range but lowered Cortrophin’s 2026 revenue guidance to $520-$540 million as its gout sales expansion entered an early commercial stage.

TradingKeyFri, Aug 7

ANI Pharmaceuticals Inc